CD274 and neoplasm: Treatment with immune checkpoint inhibitors (ICIs) in combination with chemotherapeutics can augment the prospect of TNBC therapy by enhancing the tumor-associated immune response in breast tumor cells because chemotherapy can enhance the release of antigens, tempt the expression of major histocompatibility complex (MHC) class I molecules, neoantigens, and PD-L1, and induce dendritic cell stimulation.